TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16082267

Group type: EXPERIMENTAL
Intervention: 10 mg d‐amphetamine (Treatment group, N = 4)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (Placebo group, N = 4)
Number of subjects: 8
Study: 11507929

Group type: EXPERIMENTAL
Intervention: 7.0% sodium hexametaphosphate dentifrice
Number of subjects: 159

Group type: COMPARATOR
Intervention: 5.0% ionic pyrophosphate dentifrice (control)
Number of subjects: 159
Study: 10433160

Group type: EXPERIMENTAL
Intervention: Amino acid dialysis
Number of subjects: 7

Group type: COMPARATOR
Intervention: Dextrose dialysis
Number of subjects: 7
Study: 7586936

Group type: EXPERIMENTAL
Intervention: HBOC‐201
Number of subjects: 6

Group type: COMPARATOR
Intervention: Autologous transfusion
Number of subjects: 6
Study: 2319000

Group type: EXPERIMENTAL
Intervention: FEP smooth surface
Number of subjects: 16

Group type: COMPARATOR
Intervention: CA smooth surface
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: FEP rough surface
Number of subjects: 16

Group type: COMPARATOR
Intervention: CA rough surface
Number of subjects: 16
Study: 31955699

Group type: EXPERIMENTAL
Intervention: Parecoxib
Number of subjects: 65
Study: 31523057

Group type: EXPERIMENTAL
Intervention: Clinicians viewing clinical vignettes alongside PREDICT Prostate estimates
Number of subjects: 190

Group type: COMPARATOR
Intervention: Clinicians viewing clinical vignettes with clinical information alone
Number of subjects: 190
Study: 28150384

Group type: EXPERIMENTAL
Intervention: Transitional care program
Number of subjects: 236

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 236
Study: 26062731

Group type: EXPERIMENTAL
Intervention: G-I (one session treatment of autologous haematopoietic stem cells)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: G-II (two sessions treatment of autologous haematopoietic stem cells)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: G-I (one session treatment)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: G-II (two sessions treatment)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: G-I and G-II (both groups)
Number of subjects: 90

Group type: COMPARATOR
Intervention: G-III (control group receiving regular liver treatment)
Number of subjects: 90
Study: 23184569

Group type: EXPERIMENTAL
Intervention: Spironolactone, 50 mg once daily
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Amiloride, 10 mg once daily
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 21885980

Group type: EXPERIMENTAL
Intervention: Blind Intubation Device (BID)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Macintosh laryngoscope (ML)
Number of subjects: 50
Study: 19489848

Group type: EXPERIMENTAL
Intervention: Mannitol (given first)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Mannitol (given after methacholine)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Methacholine (given first)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Methacholine (given after mannitol)
Number of subjects: 48
Study: 16769348

Group type: EXPERIMENTAL
Intervention: Enteral recombinant human G‐CSF (rhG‐CSF) for 5 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo for 5 days
Number of subjects: 18
Study: 15293593

Group type: EXPERIMENTAL
Intervention: Levalbuterol inhalation solution (Xopenex)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Racemic albuterol (R,S-albuterol)
Number of subjects: 0
Study: 11813931

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg BID (IR tablets)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Clarithromycin 1 g OD (two 500-mg MR tablets)
Number of subjects: 160
Study: 9742534

Group type: EXPERIMENTAL
Intervention: Convective warming blankets (Group 2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Heating mattress (Group 1)
Number of subjects: 50
Study: 7527112

Group type: EXPERIMENTAL
Intervention: Aprotinin (total dose 4.2 x 10(6) kallikrein inhibiting units)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (total dose 20 mg/kg body weight)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Nonmedicated controls
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Aprotinin and Tranexamic acid
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 43
Study: 3056473

Group type: EXPERIMENTAL
Intervention: Pelvic floor training
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Surgery (colposuspension)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Surgery (vaginal repair)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Pre-treatment radiologic reevaluation
Number of subjects: 52
Study: 14530867

Group type: EXPERIMENTAL
Intervention: CSA + MTX
Number of subjects: 105

Group type: COMPARATOR
Intervention: CSA alone
Number of subjects: 105

Group type: COMPARATOR
Intervention: CSA + HCQ
Number of subjects: 105
Study: 31749301

Group type: EXPERIMENTAL
Intervention: Regular moderate intensity exercise during pregnancy
Number of subjects: 855

Group type: COMPARATOR
Intervention: Standard antenatal care during pregnancy
Number of subjects: 855
Study: 30819259

Group type: EXPERIMENTAL
Intervention: Turning-based treadmill training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Regular treadmill training
Number of subjects: 18
Study: 28154462

Group type: EXPERIMENTAL
Intervention: Yunnan Baiyao (1000 mg orally every 12 h for 5 consecutive treatments)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 8
Study: 26925895

Group type: EXPERIMENTAL
Intervention: Stress management training (60-minute in-person training, 5 sessions over 8 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine training given to all patients in hemodialysis department (Control)
Number of subjects: 50
Study: 24158787

Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg/day) plus exemestane (25 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus exemestane (25 mg/day)
Number of subjects: 0
Study: 20379145

Group type: EXPERIMENTAL
Intervention: Obese CP patients
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Normal weight CP patients
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: All CP patients
Number of subjects: 54

Group type: COMPARATOR
Intervention: Obese controls
Number of subjects: 54
Study: 19395660

Group type: EXPERIMENTAL
Intervention: Supine position (Sup)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sitting position (Sit)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Supine with legs up position (SupLu)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Upright position (Up)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Post-exercise condition (post-SI)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: All positions in N condition
Number of subjects: 11
Study: 16546538

Group type: EXPERIMENTAL
Intervention: Community DOTS
Number of subjects: 907

Group type: COMPARATOR
Intervention: Family-member DOTS
Number of subjects: 907
Study: 15482516

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 11155058

Group type: EXPERIMENTAL
Intervention: Standard differential pressure valve
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Delta valve (PS Medical‐Medtronic)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Sigma valve (NMT Cordis)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Control group (differential pressure valves)
Number of subjects: 344
Study: 9340608

Group type: EXPERIMENTAL
Intervention: Double phototherapy with Wallaby optic fibers
Number of subjects: 2

Group type: COMPARATOR
Intervention: Conventional phototherapy
Number of subjects: 2
Study: 8034239

Group type: EXPERIMENTAL
Intervention: PC stored at 22 degrees C and incubated at 37 degrees C for 1 h before transfusion
Number of subjects: 22

Group type: COMPARATOR
Intervention: Non-warmed PC
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both pre-warmed and non-warmed PC
Number of subjects: 22
Study: 2950464

Group type: EXPERIMENTAL
Intervention: Phlebotomy
Number of subjects: 73

Group type: COMPARATOR
Intervention: Myelosuppression
Number of subjects: 73
Study: 29789220

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo once daily
Number of subjects: 0
Study: 28236016

Group type: EXPERIMENTAL
Intervention: Fully-covered stent
Number of subjects: 95

Group type: COMPARATOR
Intervention: Semi-covered stent
Number of subjects: 95
Study: 26710696

Group type: EXPERIMENTAL
Intervention: Sensor augmented insulin pump (SAP)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Double C therapy (continuous subcutaneous insulin infusion and retrospective continuous glucose monitoring)
Number of subjects: 81
Study: 23433188

Group type: EXPERIMENTAL
Intervention: rh-APC infusion (24 mcg kg(‐1) h(‐1) for 96 h)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 21674864

Group type: EXPERIMENTAL
Intervention: Temozolomide plus radiotherapy (RT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Radiotherapy alone (RT)
Number of subjects: 40
Study: 18783459

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 7354

Group type: EXPERIMENTAL
Intervention: Provider Counseling
Number of subjects: 7354

Group type: EXPERIMENTAL
Intervention: Provider Counseling + Pharmacotherapy
Number of subjects: 7354

Group type: EXPERIMENTAL
Intervention: Quitline with nicotine patch
Number of subjects: 7354
Study: 16568202

Group type: EXPERIMENTAL
Intervention: FDG-PET and CT imaging in patients with organising pneumonia
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: FDG-PET and CT imaging in patients with air-space consolidation
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Correlation of CD45(+) cells with maximal SUV
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Correlation of CD8(+) T lymphocytes with maximal SUV
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Correlation of CD45(+) cells with maximal LNR
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Correlation of CD8(+) T lymphocytes with maximal LNR
Number of subjects: 88
Study: 12907900

Group type: EXPERIMENTAL
Intervention: Oral protein-bound polysaccharide K plus 300 mg tegafur/uracil
Number of subjects: 201

Group type: COMPARATOR
Intervention: 300 mg tegafur/uracil alone
Number of subjects: 201
Study: 10539814

Group type: EXPERIMENTAL
Intervention: Telmisartan 10 mg
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Telmisartan 20 mg
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Telmisartan (all doses)
Number of subjects: 82
Study: 8557919

Group type: EXPERIMENTAL
Intervention: Apex defibrillation electrode on the breast
Number of subjects: 27

Group type: COMPARATOR
Intervention: Apex defibrillation electrode under the breast
Number of subjects: 27

Group type: COMPARATOR
Intervention: Apex defibrillation electrode lateral to the breast
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Apex defibrillation electrode on the breast (large-breasted group)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Apex defibrillation electrode under the breast (large-breasted group)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Apex defibrillation electrode lateral to the breast (large-breasted group)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Apex defibrillation electrode on the breast (small-breasted group)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Apex defibrillation electrode under the breast (small-breasted group)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Apex defibrillation electrode lateral to the breast (small-breasted group)
Number of subjects: 27
Study: 1752890

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 6282105

Group type: EXPERIMENTAL
Intervention: Lentils breakfast
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Lentils breakfast followed by standard bread lunch
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Slow feeding of bread breakfast over 4 hours
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Bread breakfast with a quarter of carbohydrate
Number of subjects: 7
Study: 31397288

Group type: EXPERIMENTAL
Intervention: CSLT (computerised speech and language therapy) plus usual care
Number of subjects: 278

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 278

Group type: COMPARATOR
Intervention: Attention control plus usual care
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: CSLT (computerised speech and language therapy)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 278
Study: 30221912

Group type: EXPERIMENTAL
Intervention: Probiotic-omega group (Symbiter Omega)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 48
Study: 27030846

Group type: EXPERIMENTAL
Intervention: Patients with knee OA
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 11
Study: 25248418

Group type: EXPERIMENTAL
Intervention: Hemorrhoidal dearterialization with mucopexy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hemorrhoidectomy
Number of subjects: 40
Study: 22134175

Group type: EXPERIMENTAL
Intervention: Methadone with drug abuse counseling
Number of subjects: 230

Group type: COMPARATOR
Intervention: Methadone only
Number of subjects: 230
Study: 19838742

Group type: EXPERIMENTAL
Intervention: Oncologist empathic responses to patients' negative emotion
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Patients with low economic security
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Married patients
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Patients who knew their oncologist for more than a year
Number of subjects: 264
Study: 19034342

Group type: EXPERIMENTAL
Intervention: 30 mg Mitomycin C instillation
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no further treatment)
Number of subjects: 63
Study: 10930147

Group type: EXPERIMENTAL
Intervention: Genotypic-guided therapy (G4)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (G1)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (G2)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Genotypic-guided therapy (G3)
Number of subjects: 81
Study: 9513828

Group type: EXPERIMENTAL
Intervention: Portal hypertensive gastropathy in patients with cirrhosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Portal hypertensive gastropathy in controls without cirrhosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mosaic-like pattern
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specificity of portal hypertensive gastropathy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Classification of portal hypertensive gastropathy
Number of subjects: 0
Study: 8452173

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily
Number of subjects: 191

Group type: COMPARATOR
Intervention: AMX/CP 500 mg/125 mg three times a day
Number of subjects: 191
Study: 3785797

Group type: EXPERIMENTAL
Intervention: Topical 5-fluorouracil cream (5%, applied biweekly for at least six months)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No prophylactic 5-fluorouracil cream
Number of subjects: 90
Study: 28984095

Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia and continuous wound infusion of anesthetics
Number of subjects: 96

Group type: COMPARATOR
Intervention: Local infiltration analgesia and continuous wound infusion of saline solution
Number of subjects: 96
Study: 27601354

Group type: EXPERIMENTAL
Intervention: Supervised group using mobile app
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Unsupervised group using mobile app
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Both app-using groups
Number of subjects: 139
Study: 25091593

Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive-behavioral therapy (CBT) - eight sessions led by trained psychologists on a weekly basis
Number of subjects: 216

Group type: COMPARATOR
Intervention: Usual care from primary care centers
Number of subjects: 216
Study: 24370796

Group type: EXPERIMENTAL
Intervention: Mechanical heart valve prosthesis
Number of subjects: 223

Group type: COMPARATOR
Intervention: Biological heart valve prosthesis
Number of subjects: 223
Study: 20012343

Group type: EXPERIMENTAL
Intervention: Targeted occupational health intervention
Number of subjects: 382

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 382
Study: 19441667

Group type: EXPERIMENTAL
Intervention: Escitalopram (n=51) with a dose range of 10-20 mg/day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nortriptyline (n=39) with a dose range of 75-150 mg/day
Number of subjects: 90
Study: 16820255

Group type: EXPERIMENTAL
Intervention: Olanzapine (initial dose of at least 10 mg/day, mean dose 12.2 mg/day, S.D. = 5.8)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Risperidone (initial dose of at least 3 mg/day, mean dose 4.9 mg/day, S.D. = 2)
Number of subjects: 235
Study: 12771003

Group type: EXPERIMENTAL
Intervention: N-terminal BNP (N-BNP)
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP)
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: LVEF <40% coupled to N-BNP over the group median
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: Combination of N-BNP (or BNP) with LVEF
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: N-BNP and BNP
Number of subjects: 666
Study: 10759936

Group type: EXPERIMENTAL
Intervention: PENS (percutaneous electrical nerve stimulation)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Needles alone
Number of subjects: 30
Study: 8682264

Group type: EXPERIMENTAL
Intervention: Psychological examination using CBA-H questionnaire
Number of subjects: 2705
Study: 1506124

Group type: EXPERIMENTAL
Intervention: Gincosan (60 mg ginkgo biloba + 100 mg ginseng)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gincosan (120 mg ginkgo biloba + 200 mg ginseng)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30806538

Group type: EXPERIMENTAL
Intervention: Trichiasis in adults aged ≥15 years
Number of subjects: 56349

Group type: EXPERIMENTAL
Intervention: Trachomatous inflammation—follicular (TF) in children aged 1–9 years
Number of subjects: 56349

Group type: EXPERIMENTAL
Intervention: Age-related prevalence of trichiasis
Number of subjects: 56349
Study: 26985728

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) - 3 sessions (1 in person and 2 by phone)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Control - printed literature about alcohol and drug use risks
Number of subjects: 307
Study: 25015547

Group type: EXPERIMENTAL
Intervention: Calorie labeling implementation in Philadelphia
Number of subjects: 0
Study: 22991113

Group type: EXPERIMENTAL
Intervention: Massage intervention (7-8 sessions after work period)
Number of subjects: 18
Study: 20435968

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Treatment as usual (local traditional vocational services)
Number of subjects: 219
Study: 18386573

Group type: EXPERIMENTAL
Intervention: Acupoint group (needling at Zusanli ST36)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Non-acupoint group (no needling)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Acupoint group
Number of subjects: 26
Study: 15935319

Group type: EXPERIMENTAL
Intervention: Formal model based on DEC investigation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trained police officers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formal model
Number of subjects: 0
Study: 14746378

Group type: EXPERIMENTAL
Intervention: Sleep loss (0, 2, 4, and 8 hours of sleep loss)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ethanol (0.0 g/kg, 0.3 g/kg, 0.6 g/kg, and 0.9 g/kg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sleep loss
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 32
Study: 11293914

Group type: EXPERIMENTAL
Intervention: Children born to mothers with well‐controlled diabetes
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control children
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Children born to mothers with diabetes
Number of subjects: 57
Study: 8917198

Group type: EXPERIMENTAL
Intervention: Left lung wrap-around removed (attenuation coefficient matched to heart)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Left lung wrap-around present
Number of subjects: 15

Group type: COMPARATOR
Intervention: No left lung wrap-around
Number of subjects: 15

Group type: COMPARATOR
Intervention: Filling of the left lung (in cases without wrap-around)
Number of subjects: 15
Study: 1386975

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Ondansetron 12 mg
Number of subjects: 70
Study: 6374683

Group type: EXPERIMENTAL
Intervention: Aqueous nasal spray of beclomethasone dipropionate (200 micrograms, twice daily for 2 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Pressurized nasal spray of beclomethasone dipropionate (200 micrograms, twice daily for 2 weeks)
Number of subjects: 38
Study: 31079947

Group type: EXPERIMENTAL
Intervention: ExPEC4V (4:4:4:8 μg)
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: ExPEC4V (8:8:8:16 μg)
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: ExPEC4V
Number of subjects: 848

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 848
Study: 30179727

Group type: EXPERIMENTAL
Intervention: High-cocoa group (4 g/d; 220 mg flavanols)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Middle-cocoa group (2 g/d; 110 mg flavanols)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low-cocoa group (1 g/d; 55 mg flavanols)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: All FRC-treated groups
Number of subjects: 48
Study: 27307217

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading dose of 0.5 μg/kg over 10 min, followed by continuous infusion of 0.1 μg/kg/h until the end of surgery)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control (volume-matched normal saline)
Number of subjects: 130